Knees next for Mesoblast
Tuesday, 12 August, 2008
Preclinical trials conducted by Mesoblast [ASX: MSB] have shown that the company's adult stem cells are capable of regenerating damaged knee cartilage in a post-menopausal osteoarthritis large animal model.
A single injection of adult stem cells was able to repair and regenerate knee cartilage in ewes with well established osteoarthritis even though the cells were administered three months after initial joint damage.
This effect has yet to be demonstrated by any competing products on the market, the company said.
Mesoblast executive director Professor Silviu Itescu said the results meant the company would now target both post-menopausal and post-traumatic knee osteoarthritis for product commercialisation.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
